← Back to Screener
ImageneBio, Inc. Common Stock (IMA)
Price$6.00
Favorite Metrics
Price vs S&P 500 (26W)-34.63%
Price vs S&P 500 (4W)-5.80%
Market Capitalization$65.99M
All Metrics
Book Value / Share (Quarterly)$11.91
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-62.86%
Cash Flow / Share (Quarterly)$-4.28
Price vs S&P 500 (YTD)-18.63%
Net Profit Margin (TTM)-744.28%
EPS (TTM)$-4.45
10-Day Avg Trading Volume1.97M
EPS Excl Extra (TTM)$-4.45
Revenue Growth (5Y)-38.63%
EPS (Annual)$-9.31
ROI (Annual)-34.06%
Net Profit Margin (5Y Avg)-1488.95%
Cash / Share (Quarterly)$12.10
ROA (Last FY)-29.64%
EBITD / Share (TTM)$-5.55
ROE (5Y Avg)-35.30%
Operating Margin (TTM)-823.43%
Cash Flow / Share (Annual)$-4.28
P/B Ratio0.50x
P/B Ratio (Quarterly)0.61x
Net Income / Employee (Annual)$-3
ROA (TTM)-23.49%
EPS Incl Extra (Annual)$-9.31
Current Ratio (Annual)12.49x
Quick Ratio (Quarterly)12.16x
3-Month Avg Trading Volume0.26M
52-Week Price Return-55.71%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)82.49x
Asset Turnover (Annual)0.01x
52-Week High$18.00
Operating Margin (5Y Avg)-1585.64%
EPS Excl Extra (Annual)$-9.31
26-Week Price Return-25.88%
Quick Ratio (Annual)12.16x
13-Week Price Return-13.62%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)12.49x
Enterprise Value$-28.541
Revenue / Share Growth (5Y)-9.18%
Asset Turnover (TTM)0.05x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-5712.37%
Cash / Share (Annual)$12.10
3-Month Return Std Dev72.97%
Net Income / Employee (TTM)$-2
ROE (Last FY)-34.06%
EPS Basic Excl Extra (Annual)$-9.31
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.45
ROI (TTM)-26.58%
P/S Ratio (TTM)7.21x
Pretax Margin (5Y Avg)-1498.06%
Revenue / Share (Annual)$0.16
Price vs S&P 500 (52W)-90.80%
Year-to-Date Return-14.49%
5-Day Price Return-2.48%
EPS Normalized (Annual)$-9.31
ROA (5Y Avg)-30.72%
Net Profit Margin (Annual)-5668.62%
Month-to-Date Return18.00%
EBITD / Share (Annual)$-9.72
Operating Margin (Annual)-6056.37%
ROI (5Y Avg)-35.30%
EPS Basic Excl Extra (TTM)$-4.45
P/B Ratio (Annual)0.61x
Pretax Margin (TTM)-746.05%
Book Value / Share (Annual)$11.91
Price vs S&P 500 (13W)-16.48%
Beta0.70x
P/FCF (Annual)1.39x
Revenue / Share (TTM)$0.00
ROE (TTM)-26.58%
52-Week Low$3.94
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.86
3.86
3.86
3.86
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IMAImageneBio, Inc. Common Stock | 7.21x | — | — | — | $6.00 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
ImageneBio is a clinical-stage biopharmaceutical company developing treatments for immunological and inflammatory diseases. Its lead candidate, IMG-007, is a non-depleting anti-OX40 monoclonal antibody being evaluated for atopic dermatitis.